Optical Coherence Tomography Angiography in Neovascular Age-related Macular Degeneration

Status: Recruiting

Location: See location...

Intervention Type: Device

Study Type: Observational

SUMMARY

The primary goals of this study are to use optical coherence tomography (OCT) angiography (blood vessel mapping) to: 1. diagnose the presence of new blood vessels in wet age-related macular degeneration (AMD) 2. evaluate patients undergoing treatment for wet AMD 3. determine if reduced flow to the choroid is a risk factor for developing wet AMD.

Eligibility

Participation Requirements

Sex: All

Minimum Age: 50

Maximum Age: 100

Healthy Volunteers: t

View:

• Adults aged 50 and older with clinical findings of treatment-naïve (never treated) neovascular AMD with active new blood vessel growth confirmed by clinical testing will be considered

• No evidence of retinal disease

• Refractive error greater than +3.00 diopters or -7.00 diopters (glasses Rx)

• No recent eye surgery in the last 4 months

• No significant cataract to interfere with the quality of the imaging

Locations

United States

Oregon

Casey Eye Institute, Oregon Health & Science University

RECRUITING

Portland

Contact Information

Primary

George Pacheco, COA

pachecge@ohsu.edu

503-494-7398

Backup

Denny Romfh, OD

romfhd@ohsu.edu

503-494-4351

Time Frame

Start Date: 2014-09

Estimated Completion Date: 2026-12

Participants

Target number of participants: 160

Treatments

Newly-diagnosed, untreated wet AMD

This group will be adults newly diagnosed with wet AMD who have not undergone any treatment for the condition. Their data will be gathered only once, prior to treatment.

Wet AMD undergoing as-needed treatment

This group will be adults undergoing treatment as-needed for wet AMD. They will be followed monthly over the course of 1 year.

High-risk eyes

This group will be adults with wet AMD in one eye and findings of dry AMD in the other. The eye with dry AMD will be followed every 6 months for 3 years.

Wet AMD undergoing a treat and extend strategy

This group will be adults with wet AMD undergoing treatment under the treat and extend strategy. (The treat and extend strategy increases the intervals between treatments as long as the macula remains dry.) They will be followed over the course of 1 year with extra imaging before extending follow-up intervals.

Related Therapeutic Areas

Late-Onset Retinal Degeneration

Age-Related Macular Degeneration (ARMD)

Similar Clinical Trials

View All

Optical Coherence Tomography Angiography in Neovascular Age-related Macular Degeneration

Similar Clinical Trials

A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD

A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD

A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD (ATMOSPHERE)

A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD (ATMOSPHERE)

Vitrectomy, Subretinal Tissue Plasminogen Activator and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative Age-Related Macular Degeneration (TIGER): a Phase 3, Pan-European, Two-group, Observer-masked, Superiority, Randomised Controlled Surgical Trial.

Vitrectomy, Subretinal Tissue Plasminogen Activator and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative Age-Related Macular Degeneration (TIGER): a Phase 3, Pan-European, Two-group, Observer-masked, Superiority, Randomised Controlled Surgical Trial.